Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Recruiting

• Conditions: Waldenstrom's Macroglobulinaemia Refractory

• Registration Number: NCT06200220
• Lead Sponsor: Poitiers University Hospital

Brief Summary

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-12
• Study Start: 2023-12-28
• Primary Completion: 2023-12-28
• Study First Submitted: 2023-12-28
• Study First Submitted QC: 2023-12-28
• Last Update Submitted: 2023-12-28
• Study First Posted: 2024-01-10
• Last Update Posted: 2024-01-10
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Waldenstrom's macroglobulinemia
• Treatment with Venetoclax
• Non opposition

Read More

Exclusion Criteria

none

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficiency	2018 to 2025	ORR, MRR

Secondary Outcome Measures

Name	Time	Method
Tolerance	2018 to 2025	Adverse events
Efficiency in specific population	2018 to 2025	ORR in CXCR4 mutated patients, ORR in patients previously treated with BTK inhibitors

Trial Locations

Locations (1)

CHU Poitiers; 🇫🇷 Poitiers, France